Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noemi Puig

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2022
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple MyelomaCamila Guerrero, Noemi Puig, Maria-Teresa Cedena, et al.
Blood Cancer Discovery|April 15, 2025
Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple MyelomaCamila Guerrero, Maria-Jose Larrayoz, Irache Erdozain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple MyelomaJuan-Jose Garcés, Maria-Teresa Cedena, Noemi Puig, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 14, 2023
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma PatientsMichael A Thompson, Mario Boccadoro, Xavier Leleu, et al.
Blood|February 7, 2015
The cellular origin and malignant transformation of Waldenström macroglobulinemiaBruno Paiva, Luis A Corchete, Maria-Belen Vidriales, et al.
American Journal of Hematology|November 16, 2024
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapyAintzane Zabaleta, Noemi Puig, Maria-Teresa Cedena, et al.
Blood|April 28, 2016
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patientsBruno Paiva, Maria-Teresa Cedena, Noemi Puig, et al.
Hemasphere|June 22, 2026
Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencingNatalia Buenache, Marta Lasa, Andrés Arroyo, et al.
Blood|May 22, 2025
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichmentMarta Lasa, Carmen Gonzalez, Laura Notarfranchi, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2022
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple MyelomaLuis-Esteban Tamariz-Amador, Paula Rodríguez-Otero, Ana Jiménez-Ubieto, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2022
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple MyelomaCamila Guerrero, Noemi Puig, Maria-Teresa Cedena, et al.
Blood Cancer Discovery|April 15, 2025
Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple MyelomaCamila Guerrero, Maria-Jose Larrayoz, Irache Erdozain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple MyelomaJuan-Jose Garcés, Maria-Teresa Cedena, Noemi Puig, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 14, 2023
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma PatientsMichael A Thompson, Mario Boccadoro, Xavier Leleu, et al.
Blood|February 7, 2015
The cellular origin and malignant transformation of Waldenström macroglobulinemiaBruno Paiva, Luis A Corchete, Maria-Belen Vidriales, et al.
American Journal of Hematology|November 16, 2024
Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapyAintzane Zabaleta, Noemi Puig, Maria-Teresa Cedena, et al.
Blood|April 28, 2016
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patientsBruno Paiva, Maria-Teresa Cedena, Noemi Puig, et al.
Hemasphere|June 22, 2026
Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high-sensitivity detection of ctDNA by next-generation sequencingNatalia Buenache, Marta Lasa, Andrés Arroyo, et al.
Blood|May 22, 2025
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichmentMarta Lasa, Carmen Gonzalez, Laura Notarfranchi, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 10, 2022
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple MyelomaLuis-Esteban Tamariz-Amador, Paula Rodríguez-Otero, Ana Jiménez-Ubieto, et al.
Pageof 9